PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Sethi, Varun
TI  - Potential Biomarkers for Identification of PML in MS
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 21--22
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/21.short
4100  - http://mdc.sagepub.com/content/14/29/21.full
AB  - Although natalizumab has high efficacy in patients with multiple sclerosis (MS), a risk of developing progressive multifocal leukoencephalopathy (PML) has been identified in patients exposed to it. PML is a concerning adverse event of natalizumab, as PML can cause substantial morbidity or mortality in MS patients. This article discusses the management of PML in patients with MS, the prevalence of John Cunningham virus reactivation during treatment with natalizumab, as well as the use of T2*-weighted high-resolution MRI to detect PML